Skip to main content
Log in

The plasminogen-plasmin system in malignancy

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

The study of the plasminogen-plasmin system has, in the past, contributed much to the understanding of fibrinolysis and thrombolysis. Attention is now focused on the role of the components of this system in many biologic functions. Findings of uPA, its receptor and its inhibitor in many tumor tissues and tumor cell lines, strongly implicate their involvement in tumor invasion, tumor cell proliferation and metastasis. The characteristics of the plasminogen activators, the uPA receptor and the plasminogen activator inhibitors as well as their expression and regulation in tumors and tumor cell lines are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. BachmannF: Fibrinolysis. In: VerstraeteM, VermylenJ, LijnenR, ArnoutJ (eds) Thrombosis and Haemostasis. Belgium University Press, Leuven, 1987, pp 227–266

    Google Scholar 

  2. BlasiF: Surface receptors for urokinase plasminogen activator. Fibrinolysis 2: 73–84, 1988

    Google Scholar 

  3. MilesLA, PlowEF: Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 2: 61–71, 1988

    Google Scholar 

  4. DanoK, AndreasenPA, Grondahl-HansenJ, KristensenP, NielsenLS, SkriverL: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 140–239, 1985.

    Google Scholar 

  5. LaihoM, Keski-OjaJ: Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 44: 2535–2553, 1989

    Google Scholar 

  6. MarkusG: The relevance of plasminogen activators to neoplastic growth. Enzyme 40: 158–172, 1988

    PubMed  Google Scholar 

  7. TestaJE, QuigleyJP: The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Reviews 9: 355–367, 1990

    Google Scholar 

  8. KwaanHC, KeerHN: Fibrinolysis and cancer. Sem Thromb Hemost 16: 230–235, 1990

    Google Scholar 

  9. RobbinsKC: The plasminogen plasmin system. In: ColmanRH, HirshJ, MarderVJ (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott, Philadelphia, PA (ed 2), 1987, pp 340–357

    Google Scholar 

  10. HenkinJ, MarcotleP, YangM: The plasminogen-plasmin system. Prog Cardiovasc Dis 34: 135–164, 1991

    PubMed  Google Scholar 

  11. RobbinsKC, SummariaL, HsiehB, ShahRJ: The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 242: 2332–2342, 1967

    Google Scholar 

  12. RobbinsKC, BernabeP, ArzadonL, SummariaL: NH2-terminal sequences of animal plasminogen and plasmin S-carboxymethyl heavy (A) and light (B) chain derivatives: a re-evaluation of the mechanisms of activation of plasminogen. J Biol Chem 248: 7242–7246, 1973

    PubMed  Google Scholar 

  13. AstrupT: Fibrinolysis: an overview. In: DavisonJF, RowanRM, SamamaMM, DesnoyersPC (eds) Progress in Chemical Fibrinolysis and Thrombolysis. Raven Press, New York, Vol 3, 1978, pp 1–89

    Google Scholar 

  14. Sottrup-JensenL, ClaeysH, ZajdelM, PetersenTE, MagnussonS: The primary structure of human plasminogen: Isolation of two lysine-binding fragments and one ‘mini-plasminogen’ (MW 38,000) by elastase-catalyzed-specific limited proteolysis. Prog Chem Fibrinolysis Thrombolysis 3: 191–209, 1978

    Google Scholar 

  15. PetersenTE, MartzenMR, IchinoseA, DavieEW: Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 265: 6101–6111, 1990

    Google Scholar 

  16. ClaeysH, MollaA, VerstraeteM: Conversion of NH2-terminal glutamic acid to NH2-terminal lysine human plasminogen by plasmin. Thromb Res 3: 515–523, 1973

    Google Scholar 

  17. MilesL, DahlbergC, PlowE: The cell binding domains of plasminogen and their function in plasma. J Biol Chem 263: 11928–11934, 1988

    PubMed  Google Scholar 

  18. SugiyamaN, IwamotoM, AbikoA: Effects of kringles derived from human plasminogen on fibrinolysisin vitro. Thromb Res 47: 459–468, 1987

    PubMed  Google Scholar 

  19. WimanB, LijnenHR, CollenD: On the specific interaction between the lysine-binding sites in plasminogen and complementary sites in a2-antiplasmin and in fibrinogen. Biochim Biophys Acta 579: 142–154, 1979

    PubMed  Google Scholar 

  20. ValiZ, PatthyL: The fibrin-binding site of human plasminogen. Arginines 32 and 34 are essential for fibrin affinity of the kringle 1 domain. J Biol Chem 259: 13690–13694, 1984

    PubMed  Google Scholar 

  21. SugiyamaN, SasakiT, IwamotoM, AbikoY: Binding site of a2-plasmin inhibitor to plasminogen. Biochim Biophys Acta 952: 1–7, 1988

    PubMed  Google Scholar 

  22. StevensR, PollanenJ, TapiovaaraH, LeungKC, SimPS, SalonenEM, RonneE, BehrendtN, DanoK, VaheriA: Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 108: 1987–1995, 1989

    PubMed  Google Scholar 

  23. LongstaffC, GaffneyPJ: Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry 30: 979–986, 1991

    PubMed  Google Scholar 

  24. ThorsenS: Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation influence of w-aminocarboxylic acids. Biochim Biophys Acta 393: 55–65, 1975

    PubMed  Google Scholar 

  25. MarkusG, DePasqualeJL, WisslerFC: Quantitative determination of the binding of E-aminocaproic acid to native plasminogen. J Biol Chem 253: 727–732, 1978

    PubMed  Google Scholar 

  26. MurphyJC, BuetowKH, DonovanM, HornungS, MotulskyAG, DistecheC, DyerK, SwisshelmK, GiblettE: Linkage disequilibrium of plasminogen polymorphisms and assignment of the gene to human chromosome 6q26–6q27. Am J Hum Gene 40: 338–350, 1987

    Google Scholar 

  27. RaumD, MarcusA, AlperCA: Genetic polymorphism of human plasminogen. Am J Hum Genet 32: 681–689, 1980

    PubMed  Google Scholar 

  28. RobbinsKC: Dysplasminogenemias. Prog Cardiovasc Dis 4: 295–308, 1992

    Google Scholar 

  29. HeCS, WilhelmSM, PentlandAP, MarmerBL, GrantGA, EisenAZ, GoldbergGI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86: 2632–2636, 1989

    PubMed  Google Scholar 

  30. MullinDE, RorlichST: The role of proteinases in cellular invasiveness. Biochim Biophys Acta 695: 177–214, 1983

    PubMed  Google Scholar 

  31. TryggvasonnK, HoyhtyaM, SaloT: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191–217, 1987

    PubMed  Google Scholar 

  32. O'GradyRL, UpfoldLI, StephensRW: Rat mammary carcinoma cells secrete active collagenase and active latent enzymes in the stroma via plasminogen activator. Int J Cancer 28: 509–515, 1981

    PubMed  Google Scholar 

  33. SaloT, LiottaLA, Keski-OjaJ, TurpeenieMI, HujanenT, TryggvasonnK: Secretion of basement membrane collagens degrading enzyme and plasminogen activator by transformed cells — role in metastasis. Int J Cancer 30: 669–673, 1982

    PubMed  Google Scholar 

  34. BlasiF, RiccioA, SebastiG: Human plasminogen activators. Genes and protein structures. In: BlasiF (ed) Human Genes and Diseases. John Wiley & Sons, New York, 1986, pp 377–392

    Google Scholar 

  35. NyT, ElghF, LundB: The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci USA 81: 5355–5359, 1984

    PubMed  Google Scholar 

  36. VerstraeteM, SuCAPF, TanswellP, FeuererW, CollenD: Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemost 56: 1–5, 1986

    PubMed  Google Scholar 

  37. KwaanHC, LoR, McFadzeanAJS: On the production of plasma fibrinolytic activity within veins. Clin Sci 16: 241–253, 1957

    PubMed  Google Scholar 

  38. KwaanHC, LoR, McFadzeanAJS: The production of plasma fibrinolytic activityin vivo by serotonin (5-hydroxytryptamine) creatine sulphate. Clin Sci 16: 255–259, 1957

    PubMed  Google Scholar 

  39. KwaanHC, McFadzeanAJS, CookJ: On plasma fibrinolytic activity induced by ischemia. Clin Sci 15: 245–258, 1956

    PubMed  Google Scholar 

  40. KwaanHC, LoR, McFadzeanAJS: On the lysis of thrombi experimentally produced within veins. Br J Haematol 4: 51–62, 1958

    PubMed  Google Scholar 

  41. TateKM, HigginsDL, HolmesWE, WinklerME, HeynekerHL, VeharGA: Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 26: 338–343, 1987

    PubMed  Google Scholar 

  42. BachmannF, KruithofEKO: Tissue plasminogen activator: Chemical and physiological aspects. Sem Thromb Hemost 10: 6–17, 1984

    Google Scholar 

  43. RijkenDC, WijngaardsG, CollenD: Tissue-type plasminogen activator from human tissue and cell cultures and its occurrence in plasma. In: CollenD, LijnenHR, VerstraeteM (eds) Thrombolysis, Biological and Therapeutic Properties of New Thrombolytic Agents. Churchill Livingstone, Edinburgh, 1985, pp 15–30

    Google Scholar 

  44. RanbyM, WallenP: Enzymatic properties of tissue-type plasminogen activator. In: CollenD, LijnenHR, VerstraeteM (eds) Thrombolysis, Biological and Therapeutic Properties of New Thrombolytic Agents. Churchill Livingston, Edinburgh, 1985, pp 31–48

    Google Scholar 

  45. NorrmanB, WallenP, RanbyM: Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. Eur J Biochem 149: 193–200, 1985

    PubMed  Google Scholar 

  46. SobelGW, MohlerSR, JonesNW, MillerKR, PelusoR: Urokinase: An activator of plasma profibrinolysin extracted from urine. Am J Physiol 171: 768–769, 1952

    Google Scholar 

  47. WhiteWF, BarlowGH, MozenMM: The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 5: 2160–2169, 1966

    PubMed  Google Scholar 

  48. BernikMB, KwaanHC: Origin of fibrinolytic activity in cultures of the human kidney. J Lab Clin Med 70: 650–661, 1967

    PubMed  Google Scholar 

  49. BernikMB, KwaanHC: Plasminogen activator activity in cultures form human tissues. An immunological and histochemical study. J Clin Invest 48: 1740–1753, 1969

    PubMed  Google Scholar 

  50. BernikM, KwaanHC: Inhibitors of fibrinolysis in human tissues in culture. Am J Physiol 221: 916–921, 1971

    PubMed  Google Scholar 

  51. GunzlerWA, SteffensGJ, OttingF, KimSM, FrankusE, FloheL: The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seylers Z Physiol Chem 363: 1155–1165, 1982

    PubMed  Google Scholar 

  52. HusainSS, GurewichV, LipinskiB: Purification and partial form characterization of a single-chain high-molecular-weight of urokinase from urine. Arch Biochem Biophys 220: 31–38, 1983

    PubMed  Google Scholar 

  53. BernikMB, OhlerEP: Plasminogen activator and proactivator (urokinase precursor) in lung cultures. J Am Med Wom Assoc 31: 465–472, 1976

    PubMed  Google Scholar 

  54. IchinoseA, FujikawaK, SuyamaT: The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261: 3486–3489, 1986 1983

    PubMed  Google Scholar 

  55. RajputA, DegenSF, ReichE, WallerEK, AxelrodJ, EddyRL, ShowsTB: Chromosomal locations of human tissue plasminogen activator and urokinase genes. Science 230: 672–674, 1985

    PubMed  Google Scholar 

  56. DeMunkGAW, RiijkenDC: Fibrinolytic properties of single chain urokinase-type plasminogen activator (prourokinase). Fibrinolysis 4: 1–9, 1990

    Google Scholar 

  57. PatthyL, TrexlerM, ValiZ, BanyaiL, VaradiA: Kringles: Modules specialized for protein binding. Homology of the gelatinbinding region of fibronectin with the kringle structures of proteins. FEBS Lett 171: 131–136, 1984

    PubMed  Google Scholar 

  58. LijnenHR, ZamarronC, BlaberM, WinklerME, CollenD: Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 261: 1253–1258, 1986

    PubMed  Google Scholar 

  59. MarcottePA, DudlakD, LeskiML, HenkinRJ: Characterization of a metalloproteinase which cleaves with high site specificity the Glu(143)-Leu(144) bond or urokinase. Fibrinolysis 6: 57–62, 1992

    Google Scholar 

  60. RabbaniSA, DesjardinsJ, BellAW, BanvilleE, GolzmanD: An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is motogenic for osteoblast-like cells. Biochem Biophys Res Commun 173: 1058–1064, 1990

    PubMed  Google Scholar 

  61. FaribairnS, GilbertR, OjakianG, SchwimmerR, QuigleyJP: The extracellular matrix of normal chick embryo fibroblasts: Its effect on transformed chick fibroblasts and its proteolytic degradation by the transformation. J Cell Biol 101: 1790–1798, 1985

    PubMed  Google Scholar 

  62. AokiN, HarpelPC: Inhibitors of the fibrinolytic enzyme system. Sem Thromb Hemost 10: 24–41, 1984

    Google Scholar 

  63. CollenD: Report of meeting of the subcommittee on fibrinolysis. San Diego. Thromb Hemostasis 54: 803, 1985

    Google Scholar 

  64. NyT, SawdeyM, LawrenceD, MillanJL, KoskutoffDJ: Cloning and sequence of a cDNA coding for the human B-migrating endothelial-cell-type plasminogen activator. Proc Natl Acad Sci USA 83: 6776–6780, 1986

    PubMed  Google Scholar 

  65. PannekoekH, VeermanH, LambersH, DiergaarseP, VerweijCL, VanZonneveldAJ, VanMourikJA: Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family. EMBO J 5: 2539–2544, 1986

    PubMed  Google Scholar 

  66. GinsburgD, ZehebR, YangAY, RaffertyUM, AndreasenPA, NielsenL, DanoK, LeboRV, GelehrterTC: cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 78: 1673–1680, 1986

    PubMed  Google Scholar 

  67. WunTC, KretzmerKK: cDNA cloning and expression of E coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell. FEBS Lett 210: 11–16, 1987

    PubMed  Google Scholar 

  68. KruithofEKO, Tran-ThangC, RansijnA, BachmannF: Demonstration of a fast-acting inhibitor of plaminogen activators in human plasma. Blood 64: 907–913, 1984

    PubMed  Google Scholar 

  69. Juhan-VagueI, MoermanB, DeCockF, AillaudMF, CollenD: Plasma levels of a specific inhibitor of tissuetype plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 33: 523–530, 1984

    PubMed  Google Scholar 

  70. SprengersED, PrincenHMG, KooistraT, VanHinsberghVWM: Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 105: 751–758, 1985

    PubMed  Google Scholar 

  71. KwaanHC, SuwanwelaN: Inhibitors of fibrinolysis in platelets in polycythaemia vera and thrombocytosis. Br J Haematol 21: 313–322, 1971

    PubMed  Google Scholar 

  72. SprengersED, AkkermanJW, JansenBG: Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitors in human blood. Thromb Haemostasis 55: 325–329, 1986

    Google Scholar 

  73. KruithofEKO, Tran-ThangC, BachmannF: Studies on the release of a plasminogen activator in inhibitor by human platelets. Thromb Haemostasis 55: 201–205, 1986

    Google Scholar 

  74. ColucciM, ParamoJA, CollenD: Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75: 818–824, 1985

    PubMed  Google Scholar 

  75. EmeisJJ, KooistraT: Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue type plasminogen activatorin vivo and in cultured endothelial cells. J Exp Med 163: 1260–1266, 1986

    PubMed  Google Scholar 

  76. ParamoJA, ColucciM, CollenD, van derWerfF: Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 291: 573–574, 1985

    Google Scholar 

  77. D'AngeloA, KluftC, VerheijenJH, RijkenDC, MozziE, MannucciPM: Fibrinolytic shut-down after surgery: Impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest 15: 308–312, 1985

    PubMed  Google Scholar 

  78. LevinEG, SantellL: Association of a plasminogen activator inhibitor with the growth substrata and membrane of human endothelial cells. J Cell Biol 105: 2543–2549, 1987

    PubMed  Google Scholar 

  79. KawanoT, MorimotoK, UemuraY: Urokinase inhibitor in human placenta. Nature London 217: 253–254, 1968

    PubMed  Google Scholar 

  80. WohlwendA, BelinD, VassalliJD: Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 165: 320–339, 1987

    PubMed  Google Scholar 

  81. AstedtB, LacanderI, NyT: The placental type plasminogen activator inhibitor PAI-2. Fibrinolysis 1: 203–208, 1987

    Google Scholar 

  82. SchleuningWD, MedcalfRL, HessionC, RothenbuhlerR, ShawA, KruithofEKO: Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 7: 4564–4567, 1987

    PubMed  Google Scholar 

  83. YeRD, WunTW, SadlerJE: cDNA cloning and expression in Escherichia coli of plasminogen activator inhibitor from human placenta. J Biol Chem 262: 3718–3725, 1987

    PubMed  Google Scholar 

  84. WebbAC, CollinsKL, SnyderSE, AlexanderSJ, RosenwasserLJ, EddyRL, ShowsTB, AuronPE: Human monocyte arg-serpin cDNA. Sequence, chromosomal assignment and homology to plasminogen activator inhibitor. J Exp Med 166: 77–94, 1987

    PubMed  Google Scholar 

  85. GentonC, KruithofEKO, SchleuningWD: Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase type plasminogen activator in human U-937 lymphoma cell. J Cell Biol 104: 705–712, 1987

    PubMed  Google Scholar 

  86. BelinD, WohlwendA, SchleuningWD, KruithofEK, VassalliJD: Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activator inhibitor 2. EMBO J 8: 3287–3294, 1989

    PubMed  Google Scholar 

  87. KruithofEKO, VassalliJD, SchleuningWD, MattalianoRJ, BachmannF: Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 261: 11207–11213, 1986

    PubMed  Google Scholar 

  88. ChristensenU, HolmbergL, BlahaB, AstedtB: Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue. Thromb Heamostasis 48: 24–26, 1982

    Google Scholar 

  89. LecanderI, AstedtB: Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haemat 62: 221–228, 1986

    Google Scholar 

  90. HeebMJ, EspanaF, GeigerM, CollenD, StumpDC, GriffinJH: Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor 3. J Biol Chem 262: 15813–15816, 1987

    PubMed  Google Scholar 

  91. BakerJB, LowDA, SimmerRL, CunninghamDD: Protease nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21: 37–45, 1980

    PubMed  Google Scholar 

  92. EatonDL, BakerJB: Evidence that a variety of cultured cells secrete protease nexin and produce a distinct cytoplasmin serine protease inhibitor. J Cell Physiol 117: 175–182, 1983

    PubMed  Google Scholar 

  93. KoideT, FosterD, YoshitakeS, DavieEW: Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its DNA. Biochemistry 25: 2220–2225, 1986

    PubMed  Google Scholar 

  94. SilversteinRL, LeungLLK, NachmanRI: Thrombospondin: A versitle multifunctional glycoprotein. Arteriosclerosis 6: 245–253, 1986

    PubMed  Google Scholar 

  95. NielsenLS, KellermanGM, BehrendtN, PiconeR, DanoK, BlasiF: A 55,000–60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 263: 2358–2363, 1988

    PubMed  Google Scholar 

  96. RoldanAL, CubellisMW, MasucciMT, BehrendtN, LundLR, DanoK, AppellaE, BlasiF: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467–474, 1990

    PubMed  Google Scholar 

  97. PlougM, RonneE, BehrendtN, JensenAL, BlasiF, DanoK: Cellular receptor for urokinase plasminogen activator: Carboxylterminal processing and membrane anchoring by glycosylphosphatidylinositol. J Biol Chem 266: 1926–1933, 1991

    PubMed  Google Scholar 

  98. PlougM, BehrendtN, LoberD, DanoK: Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Sem Throm Hemost 17: 183–193, 1991

    Google Scholar 

  99. PlougM, PlesnerT, RonneE, EllisV, Hoyer-HansenG, HansenNE, KanoK: The receptor for urokinase-type plasminogen activator is deficient of peripheral blood leukocytes in patients with paroxysal nocturnal hemoglobinuria. Blood 79: 1447–1455, 1992

    PubMed  Google Scholar 

  100. VassalliJD, BaccinoD, BelinD: A cellular binding site for the Mr55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86–92, 1985

    PubMed  Google Scholar 

  101. StoppelliMP, CortiA, SoffientiniA, CassaniG, BlasiF, AssoianRK: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activators to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82: 4939–4943, 1985

    PubMed  Google Scholar 

  102. AppellaE, RobinsonEA, UllrichSJ, StoppelliMP, CortiA, CassaniG, BlasiF: The receptor-binding sequence of urokinase. A biological function of the growth factor module of protease. J Biol Chem 262: 4437–4440, 1987

    PubMed  Google Scholar 

  103. BlasiF: Surface receptors for urokinase plasminogen activator. Fibrinolysis 2: 73–84, 1988

    Google Scholar 

  104. PiconeR, KajtaniakEL, NielsenLS, BehrendtN, MastronocolaMR, CubellisMV, StopelliMP, PedersenS, DanoK, BlasiF: Regulation of urokinase receptors in monocyte-like U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 108: 693–702, 1989

    PubMed  Google Scholar 

  105. EllisV, ScullyMF, KakkarVV: Plasminogen activator initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 264: 2185–2188, 1989

    PubMed  Google Scholar 

  106. EllisV, DanoK: Plasminogen activation by receptor-bound urokinase. Sem Thromb Hemost 17: 194–200, 1991

    Google Scholar 

  107. Ellis V, Behrendt H, Dano K: Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem 12752–12758, 1991

  108. BoydD, FlorentG, KimP, BrattainM: Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48: 3112–3116, 1988

    PubMed  Google Scholar 

  109. EllisV, WunTC, BehrendtH, RonneE, DanoK: Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 265: 9904–9908, 1990

    PubMed  Google Scholar 

  110. PollanenJ, SakselaO, SalonenEM, AndreasenP, NielsenL, DanoK, VaheriA: Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 104: 1085–1096, 1987

    PubMed  Google Scholar 

  111. TakahashiK, KwaanHC, KohE, TanabeM: Enzymatic properties of the phosphorylated urokinase-type plasminogen activator isolated from a human carcinomatous cell line. Biochem Biophys Res Commun 182: 1473–1481, 1992

    PubMed  Google Scholar 

  112. TakahashiK, KwaanHC, IkeoK, KohE: Phosphorylation of a surface receptor bound urokinase type plasminogen activator in a human metastatic carcinomatous cell line. Biochem Biophys Res Commun 182: 1466–1472, 1992

    PubMed  Google Scholar 

  113. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1079–1085, 1990

  114. HollasW, BoydD: Regulation of the urokinase receptor by its plasminogen activator. Thromb Haemostasis 66: 678–683, 1991

    Google Scholar 

  115. BussoN, BelinD, Failly-CrepinC, VassalliJD: Plasminogen activators and their inhibitors in human mammary cell line (HBL-100): Modulation by glucocorticoids. J Biol Chem 261: 9309–9315, 1986

    PubMed  Google Scholar 

  116. GelehrterTD, Sznycer-LaszukR, ZehebR: Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity; paradoxical induction of both tPA antigen and plasminogen activator inhibitor. Mol Endocrin 1: 97–101, 1987

    Google Scholar 

  117. OhlssonM, PengXR, LiuYX, JaiXC, HsuehAJW, NyT: Hormone regulation of tissue-type plasminogen activator gene expression and plasminogen activator mediated proteolysis. Sem Thromb Hemost 17: 286–290, 1991

    Google Scholar 

  118. StricklandS, BeersWH: Studies on the role of plasminogen activator in ovulation. J Biol Chem 18: 5694–5702, 1976

    Google Scholar 

  119. HoviT, SakselaO, VaheriA: Increased secretion of plasminogen activator by human macrophages after exposure to leukocyte interferon. FEBS Lett 129: 233–236, 1981

    PubMed  Google Scholar 

  120. CollartMA, BelinD, VassalliJD, deRosodoS, VassalliP: Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin-1 and urokinase genes which are controlled by short-lived repressors. J Exp Med 164: 2113–2118, 1986

    PubMed  Google Scholar 

  121. EmeisJJ, KooistraT: Interleukin 1 and lipopolysaccharide induce and inhibitor of tissue-type plasminogen activatorin vivo and in cultured endothelial cells. J Exp Med 163: 1260–1266, 1966

    Google Scholar 

  122. SchleefRR, BeavlacquaMP, SawdwyM: Cytokine activation of vascular endothelium: Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263: 5797–5803, 1988

    PubMed  Google Scholar 

  123. GalwayB, OikawaM, NyT, HsuehAV: Epidermal growth factor stimulates tissue plasminogen activator activity and messenger ribonucleic acid levels in cultured rat granulosa cells: Mediation by pathways independent of protein kinase A and C. Endocrinol 125: 126–135, 1989

    Google Scholar 

  124. KesslerTL, MarkusG: Epidermal growth factor and 12-Tetradecanoyl phorbol 13-acetate induction of urokinase in A431 cells. Sem Thromb Hemost 17: 217–224, 1991

    Google Scholar 

  125. Keski-OjaJ, KoliK, LohiJ, LaihoM: Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Sem Thromb Hemost 17: 231–239, 1991

    Google Scholar 

  126. VanHinsbergVWM, van denBergEA, FiersW, DooijewaardG: Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 75: 1991–1998, 1990

    PubMed  Google Scholar 

  127. LevinEG, LoskutoffDJ: Regulation of plasminogen activator production by cultured endothelial cells. Ann NY Acad Sci 401: 184–194, 1982

    PubMed  Google Scholar 

  128. GospodarwoiczD, FerraraN, SchweigererL, NeufeldG: Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8: 95–114, 1987

    PubMed  Google Scholar 

  129. UnsickerK, Reichert-PreibschH, SchmidtR, PettmanB, LabourdetteG, SensenbrennerM: Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons. Proc Natl Acad Sci USA 84: 5459–5463, 1987

    PubMed  Google Scholar 

  130. MoscatelliD, PrestaM, RifkinDB: Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis and migration. Proc Natl Acad Sci USA 83: 2091–2095, 1986

    PubMed  Google Scholar 

  131. PrestaM, MoscatelliD, Joseph-SilversteinJ, RifkinDB: Purification from a hepatoma cell line a basic fibroblast growth factor-like molecule which stimulates capillary endothelial cell plasminogen activator production, DNA synthesis and migration. Mol Cell Biol 6: 4060–4066, 1986

    PubMed  Google Scholar 

  132. SakselaO, MoscatelliD, RifkinDB: The opposing effects of basic fibroblast growth factor and transforming growth factor B on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 105: 957–963, 1987

    PubMed  Google Scholar 

  133. BjorkerudS: Impaired fibrinolysis-induced capacity for postinjury phenotype of cultivated human arterial and human atherosclerotic intimal smooth muscle cells. Circulation Res 62: 1011–1018, 1988

    PubMed  Google Scholar 

  134. RossG, GlomsetJ, KariyaB, HarkerL: A platelet-derived serum factor that stimulates the proliferation of arterial smooth muscle cellsin vitro. Proc Natl Acad Sci USA 71: 1207–1210, 1974

    PubMed  Google Scholar 

  135. Bowen-PopeDF, RossR, SeifertRA: Locally acting growth factors for vascular smooth muscle cells: endogenous synthesis and release from platelets. Circulation 72: 735–740, 1985

    PubMed  Google Scholar 

  136. LinHS, GordonS: Secretion of plasminogen activator by bone marrow-derived mononuclear phagocytes and its enhancement by colony-stimulating factors. J Exp Med 150: 231–245, 1979

    PubMed  Google Scholar 

  137. SakselaO, RifkinDB: Cell-associated plasminogen activation: Regulation and physiological functions. Ann Rev Cell Biol 4: 93–126, 1988

    PubMed  Google Scholar 

  138. Keski-OjaJ, BlasiF, LeofEB, MosesHL: Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol 106: 451–459, 1988

    PubMed  Google Scholar 

  139. SakselaO: Plasminogen activation of regulation of pericellular proteolysis. Biochim Biophys Acta 823: 35–65, 1985

    PubMed  Google Scholar 

  140. LyonsRM, Keski-OjaJ, MosesHL: Proteolytic activation of latent transforming growth factor B from fibroblast conditioned medium. J Cell Biol 106: 1659–1665, 1988

    PubMed  Google Scholar 

  141. SatoY, TsuboiR, LyonsR, MosesHL, RifkinDB: Characterization of the activation of latent TGFB by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system. J Cell Biol 111: 757–763, 1990

    PubMed  Google Scholar 

  142. TestaJE, MedcalfRL, CajorJF, SchleuningWD, SordatB: Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells. Int J Cancer 43: 816–822, 1989

    PubMed  Google Scholar 

  143. BellSM, BrackenburyRW, LeslieND, DegenJL: Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters. J Biol Chem 265: 1333–1338, 1990

    PubMed  Google Scholar 

  144. TrousseauA: Phlegmasia alba dolens. In: Clinique Medicale de Hotel Dieu de Paris. Balliere, Paris, 2nd Ed, Vol 3, 1865, p 654

    Google Scholar 

  145. EsparazB, KiesMS, KwaanHC: Thromboembolism and cancer. In: KwaanHC, SamamaMM (eds) Clinical Thrombosis. CRC Press, Inc., Boca Raton, FL 1989, pp 317–334

    Google Scholar 

  146. JamesGI, MathesonNM: Thrombophlebitis in cancer. Practitioner 134: 683–684, 1935

    Google Scholar 

  147. ThompsonAP: Thrombosis of the peripheral veins in visceral cancer. Clin J 67: 137–143, 1938

    Google Scholar 

  148. SproulEE: Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body of tail of the pancreas with multiple venous thromboses. Am J Cancer 34: 566–582, 1938

    Google Scholar 

  149. KenneyWE: The association of carcinoma in the body and tail of the pancreas with multiple venous thrombi. Surgery 14: 600–609, 1943

    Google Scholar 

  150. InnerfeldI, AnristA, BenjaminJW: Plasma antithrombin patterns in disturbances of the pancreas. Gastroenterol 19: 843–851, 1951

    Google Scholar 

  151. CoonW, CollerF: Some epidemiologic considerations of thromboembolism. Surg Gynecol Obstet 109: 485–487, 1959

    Google Scholar 

  152. PhillipsLL, SkrodelisV, FureyCA: The fibrinolytic enzyme system in prostatic cancer. Cancer 12: 721–732, 1959

    PubMed  Google Scholar 

  153. HalpertB, MakkL, JordanG: A retrospective study of 120 patients with carcinoma of the pancreas. Surg Gynecol Obstet 121: 91–103, 1965

    Google Scholar 

  154. MillerSP, Sanchez-AvalosJ, StefanskiT: Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer 20: 1452–1465, 1967

    PubMed  Google Scholar 

  155. FriemanDG: Venous thromboembolic disease in malignant states. In: Thrombosis. Natl Acad, Washington, DC, 1969, p 5

    Google Scholar 

  156. DavisRB, TheologidesA, KennedyBJ: Comparative studies of blood coagulation and platelet aggregation in patients with cancer and non-malignant diseases. Ann Intern Med 71: 67–80, 1969

    PubMed  Google Scholar 

  157. BrugarolasA, MikIB, EliasEG, MittelmanA: Correlation of hyperfibrinogenemia with major thromboembolism in patients with cancer. Surg Gynecol Obstet 136: 75–77, 1981

    Google Scholar 

  158. SlichterSJ, HarkerLA: Hemostasis in malignancy. Ann NY Acad Sci 230: 252–261, 1974

    PubMed  Google Scholar 

  159. PineoGF, BrainMC, GallusAS, HirshJ, HattonMW, RegoecziE: Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 23: 262–270, 1974

    Google Scholar 

  160. WajimaT: Thrombophlebitis in cancer patients. Ann NY Acad Sci 370: 138–144, 1981

    PubMed  Google Scholar 

  161. EdwardsEA: Migrating thrombophlebitis associated with carcinoma. N Eng J Med 1031: 204–212, 1959

    Google Scholar 

  162. SchmaierAH, DayJH: A classification of disorders of hemostasis and thrombosis in patients with malignancy. Prog Clin Biol Res 89: 1–20, 1982

    Google Scholar 

  163. RennieJW, OgstonD: Fibrinolytic activity in malignant disease. J Clin Pathol 28: 872–874, 1975

    PubMed  Google Scholar 

  164. OgstonD, DawsonAA: The fibrinolytic system in malignant lymhomas. Acta Haematologica 49: 89–95, 1973

    PubMed  Google Scholar 

  165. GoreM, MillerKE, SoongSJ, Clarke-PearsonDL, PizzoSV: Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. Am J Obstet Gynecol 149: 830–834, 1985

    Google Scholar 

  166. RennieJA, OgstpmD: Fibrinolytic activity in malignant disease. J Clin Path 28: 872–874, 1975

    PubMed  Google Scholar 

  167. DeJongE, KnotEAR, PikerD, IburgAHC, RijkenCD, VeenhofKHN, DooijewaardG, TenCateJW: Increased plasminogen activator inhibition levels in malignancy. Thromb Haemost 57: 140–143, 1987

    PubMed  Google Scholar 

  168. KirchheimerJC, HuberK, WagnerO, BinderBR: Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol 66: 85–89, 1987

    PubMed  Google Scholar 

  169. ParamoJA, CampbellW, CuestaB, GomezC, ArandaA, RochaE: Fibrinolytic response in malignancy. Fibrinolysis 1: 195–199, 1987

    Google Scholar 

  170. ParamoRE, FernandezFJ, CuestaB, HernandezM, PalomaMJ, RifonJ: Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 54: 699–707, 1989

    PubMed  Google Scholar 

  171. KwaanHC, LoR, McFadzeanAJS: Antifibrinolytic activity in primary carcinoma of the liver. Clin Sci 18: 251–261, 1959

    PubMed  Google Scholar 

  172. GralnickHR, GivelberH, AbramsE: Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. N Eng J Med 299: 221–232, 1978

    Google Scholar 

  173. TsudaH, OkaK, NoutsukaY, SueishiK: Tissue-type plasminogen activator in patients with intracranial meningiomas. Thromb Haemost 60: 508–513, 1988

    PubMed  Google Scholar 

  174. TallmanMS, KwaanHC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79: 543–553, 1992

    PubMed  Google Scholar 

  175. RuoslahtiE: Fibronectin and its receptors. Ann Rev Biochem 57: 375–413, 1988

    PubMed  Google Scholar 

  176. HynesRO: Integrins: A family of cell surface receptors. Cell 48: L549–554, 1987

    Google Scholar 

  177. RuoslahtiE, PierschbacherMD: New perspectives in cell adhesion, RGC and integrins. Science 238: 491–497, 1987

    PubMed  Google Scholar 

  178. MurphyG, DochertyAJP: Molecular studies on the connective tissue metalloproteinases and their inhibitor TIMP. In: GalauertL (ed) The Control of Tissue Damage. Elsevier, NY, 1988, pp 223–241

    Google Scholar 

  179. WerbZ, MainardiCL, VaterCA, HibbsMS, HartyKA: Endogenous activation of latent collagenase by rheumatoid synovial cells: Evidence for a role of plasminogen activator. N Eng J Med 296: 1017, 1977

    Google Scholar 

  180. SchulzRM, SilbermanS, PerskyB, BajkowskiAS, CarmichaelPF: Inhibition by human recombinant tissue inhibitor of metalloproteinase of human amnion invasion and lung colonization by murine B16-FID melanoma cells. Cancer Res 48: 5539–5545, 1988

    PubMed  Google Scholar 

  181. CawstonTE, NobelDN, MurphyG, SmithAJ, WoodleyC, HazlemanB: Rapid pufification of tissue inhibition of metalloproteinase from human plasma and identification as a serum G protein. Biochem J 239: 677–682, 1986

    Google Scholar 

  182. JanickeF, SchmittM, UlmK, GossnerW, GraeffH: The urokinase type plasminogen activator (uPA) antigen is related to early relapse in breast cancer. Lancet (ii): 1049, 1989

    Google Scholar 

  183. DuffyMJ, O'GradyP, DevaneyD, SiorainLO, FenellyJJ, LijnenHR: Tissue plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48: 1348–1349, 1988

    PubMed  Google Scholar 

  184. DuffyMJ, O'GradyP, DevaneyD, O'SiorainL, FennellyJJ, LijnenHJ: Urokinase plasminogen activator: A marker for aggressive breast carcinomas: Preliminary report. Cancer 52: 531–533, 1988

    Google Scholar 

  185. JanickeF, SchmittM, GraeffH: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Sem Thromb Hemost 17: 303–313, 1991

    Google Scholar 

  186. DeRuinPA, GriffioenG, VerspagetHW, VerheijenJH, LamersCBHW: Plasminogen activators and tumor development in the human colin: Activity levels in normal mucosa, adenomatous tissues, polyps and adenocarcinomas. Cancer Res 47: L4654–4657, 1987

    Google Scholar 

  187. SappinoAP, HuarteJ, BelinD, VassalliJD: Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol 109: 2471–2479, 1989

    PubMed  Google Scholar 

  188. FeinbergRF, KaoLC, HaimowitzJE, QueenanJTJr, WunTC, StrassJFIII, KlimanHJ: Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker for invading trophoblasts. Lab Invest 61: 20–26, 1989

    PubMed  Google Scholar 

  189. MenoudPA, DebrotS, SchowingJ: Mouse neural crest cells secrete both urokinase type and tissue type plasminogen activatorsin vitro. Development 106: 685–690, 1989

    PubMed  Google Scholar 

  190. EricksonCA, IsseroffRR: Plasminogen activator activity is associated with neural crest cell motility in tissue culture. J Exp Zool 251: 123–133, 1989

    PubMed  Google Scholar 

  191. ValinskyJE, ReichE, LeDouarinN: Plasminogen activator in the bursa of Fabricius: Correlations with morphogenetic remodeling and cell migrations. Cell 25: 471–476, 1981

    PubMed  Google Scholar 

  192. GudewiczPW, GilboaN: Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Commun 147: 1176–1181, 1987

    PubMed  Google Scholar 

  193. KrawczykWK: A pattern of epidermal cell migration during wound healing. J Cell Biol 49: 247–263, 1971

    Google Scholar 

  194. AstrupT: Blood coagulation and fibrinolysis in tissue culture and tissue repair. Biochem Pharmacol 17 (Suppl): 241–257, 1968

    PubMed  Google Scholar 

  195. ViziamCB, MatolstyAG, MesconH: Epithelialization of small wounds. J Invest Dermatol 43: 499–507, 1964

    PubMed  Google Scholar 

  196. QuaxPHA, RrisalE, PedersenN, BonavaudS, VerheijenJH, BlasiF, Barlovatz-Meimon: Cell surface plasminogen activation is required for differentiation of human adult myogenic cellsin vitro. Thromb Hemost 65 (Abstr): 665, 1991

    Google Scholar 

  197. ClowesAW, MonikaM, ClowesYPT, AuYPT, ReidyMA, BelinD: Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator durmigration in injured rat carotid artery. Cir Res 67: 61–67, 1990

    Google Scholar 

  198. GrossTJ, SimonRH, SitrinRG: Expression of urokinasetype plasminogen activator by rat pulmonary alveolar epithelial cells. Am J Respir Cell Mol Biol 3: 449–456, 1990

    PubMed  Google Scholar 

  199. MarshallBC, SageserDS, RaoNV, EdmilM, HoidalJR: Alveolar epithelial cell plasminogen activator. Characterization and regulation. J Biol Chem 265: 8198–8204, 1990

    PubMed  Google Scholar 

  200. LayerGT, BernardKG, GaffneyPJ, Cederholm-WilliamsSA, MahmoudM, HoulbrookS, PattisonM: Tissue plasminogen activators in breast cancer. Thromb Res 45: 601–607, 1987

    PubMed  Google Scholar 

  201. Mira-y-LopezR, OsborneMP, DePaloAJ, OssowskiL: Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas; correlation with clinical outcome of antiestrogen therapy. Intl J Cancer 47: 827–832, 1991

    Google Scholar 

  202. DuffyMJ, ReillyD, O'sullivanC, O'HigginsN, FennellyJJ, AndreasenP: Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827–6829, 1990

    PubMed  Google Scholar 

  203. DuffyMJ, ReilleyD, O'SullivanC, O'HigginsN, FennellyJJ: Urokinase plasminogen activator and prognosis in breast cancer. Lancet (i): 108, 1990

    Google Scholar 

  204. Reilly D, Andreasen P, Duffy MJ: Urokinase type plasmiinogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA levels. J Biochem Soc Trans 19: 44S, 1991

  205. ReillyD, ChristensenL, DuchM, NolanN, DuffyMJ, AndreasenPA: Type 1 plasminogen activator inhibitor in human breast carcinomas. Intl J Cancer 50: 208–214, 1992

    Google Scholar 

  206. KirchheimerJ, LollerA, BinderBR: Isolation and characterization of plasminogen activators from hypersplenic and malignant prostate tissue. Biochim Biophys Acta 797: 256–265, 1984

    PubMed  Google Scholar 

  207. KollerA, KirchheimerJ, PflugerH, BinderBR: Tissue plasminogen activator activity in prostate cancer. Eur Urol 10: 389–394, 1984

    PubMed  Google Scholar 

  208. KirchheimerJC, PflugerH, RitschalP, HeinertG, BinderBR: Plasminogen activator activity in bone metastasis as compared to primary tumors. Invasion Metastasis 5: 344–355, 1985

    PubMed  Google Scholar 

  209. HienertG, KirchheimerJC, PflugerH, BinderBR: Urokinase type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 140: 1466–1469, 1988

    PubMed  Google Scholar 

  210. GaylisFD, KeerHN, WilsonMJ, KwaanHC, SinhaAA, KozlowskiJM: Plasminogen activator in human prostate cancer cell lines and tumors. Correlation with aggressive phenotype. J Urol 142: 193–198, 1989

    PubMed  Google Scholar 

  211. KeerHN, GayulisFD, KozlowskiJM, KwaanHC, BauerKD, AkouchiA, SinhaAA, WilsonMJ: Heterogeneity in cellular level of expression of plasminogen activators in human prostate cancer cell lines. Invasive cells contain and secrete more uPA. The Prostate 18: 201–204, 1991

    PubMed  Google Scholar 

  212. MarkusG, CamioloSM, KohgaS, MadjeaJM, MittelmanA: Plasminogen activator secretion of human tumors in short-term organ cultures, including a comparison of primary and metastatic colon tumors. Cancer Res 43: 5517–5525, 1983

    PubMed  Google Scholar 

  213. KohgaS, HarverySR, WeaverRM, MarkusG: Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res 45: 1787–1796, 1985

    PubMed  Google Scholar 

  214. BoydD, FlorentG, KimP, BrattainM: Determinations of the levels of urokinase and its receptors in human colon carcinoma cell lines. Cancer Res 48: 3112–3116, 1988

    PubMed  Google Scholar 

  215. deBruinPAF, GriffioenG, VerspagetHW, VerheijenJH, DooijewaardG, van denInghHF, LamersCBHW: Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 48: 4520–4524, 1988

    PubMed  Google Scholar 

  216. BoydD, ZioberB, ChakrabartyS, BrattainM: Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res 49: 816–820, 1989

    PubMed  Google Scholar 

  217. SchlechteW, MuranoG, BoydD: Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 49: 6064–6069, 1989

    PubMed  Google Scholar 

  218. PykeC, KristensenP, RalfkiaerE, Grondahl-HansenJ, EriksenJ, BlasiF, DanoK: Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059–1067, 1991

    PubMed  Google Scholar 

  219. HollasW, BoydD: Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptors. Sem Thromb Hemost 17: 225–230, 1991

    Google Scholar 

  220. MarkusG, TakitaH, CamioloSM, CorasantiJG, EversJL, HobikaCH: Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 40: 841–848, 1980

    PubMed  Google Scholar 

  221. TakahashiK, GojoboriT, TanifujiM: Two-color cytofluorometry and cellular properties of the urokinase receptor associated with a human metastatic carcinomatous cell line. Exp Cell Biol 192: 405–413, 1991

    Google Scholar 

  222. SeiffertD, MimuroJ, SchleefRR, LoskutoffDJ: Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ Dev 32: 287–292, 1990

    PubMed  Google Scholar 

  223. KirchheimerJC, WojtaJ, ChristG, BinderB: Proliferation of a human epidermal tumor cell line stimulated by urokinase. Proc Natl Acad Sci USA FASEB 1: 125–128, 1987

    Google Scholar 

  224. KirchheimerJC, WojtaJ, ChristG, BinderBR: Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 86: 5424–5428, 1989

    PubMed  Google Scholar 

  225. GoltzmanD, BolivarI, MorozLA, RabbaniSA: Urokinase and the mechanism of osteoblastic metastases by prostate cancer. Fibrinolysis 1: 63–69, 1992

    Google Scholar 

  226. KirchheimerJC, WojtaJ, ChristG, HienertG, BinderBR: Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells. Carcinogenesis 9: 2121–2123, 1988

    PubMed  Google Scholar 

  227. KirchheimerJC, ChristG, BinderBR: Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem 181: 103–107, 1987

    Google Scholar 

  228. WeissL: Cancer cell traffic from the lung to the liver: An example of metastatic inefficiency Int J Cancer 25: 385–392, 1980

    PubMed  Google Scholar 

  229. MelzerMS: Macrophage activation for tumor cytoxicity characterization of primary and trigger signals during lymphokine activation. J Immunol 127: 179–183, 1981

    PubMed  Google Scholar 

  230. HannaN: Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of NK cell-mediated cytotoxicity. Int J Cancer 26: 675–680, 1980

    PubMed  Google Scholar 

  231. RosenbertSA, SpiessP, LafrenierR: A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 223: 1318–1321, 1986

    Google Scholar 

  232. RosensteinM, YoonI, KaufmanY, RosenbergSA: Lymphokine activated killer cells: Lysis of fresh syngeneic NK-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 44: 1946–1953, 1984

    PubMed  Google Scholar 

  233. FidlerIJ, GerstenDN, HartIR: Pathogenesis of cancer metastasis. Adv Cancer Res 28: 149–260, 1978

    PubMed  Google Scholar 

  234. SchirmacherV: Cancer metastasis: Experimental approaches, theoretical concepts and impacts for treatment strategy. Adv Cancer Res 43: 69–71, 1985

    Google Scholar 

  235. NicolsonGL: Cancer metastasis: Organ colonization and the surface properties of malignant cells. Biochim Biophys Acta 695: 113–176, 1982

    PubMed  Google Scholar 

  236. GorelikE: Protective effect of fibrin on tumor metastasis. Fibrinolysis 1: 35–38, 1992

    Google Scholar 

  237. TuszynskiGP, GasicTB, RothmanVL, KnudsenKA, GlasicGI: Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47: 4130–4133, 1987

    PubMed  Google Scholar 

  238. FukaoH, TanakaN, UeshimaS, OkadaK, YasutomiM, MatsuoO: Plasminogen activator inhibitor in stomach and colorectal carcinomas. Sem Thromb Hemost 17: 276–279, 1991

    Google Scholar 

  239. SappinoAP, BelinD, HuarteJ, Hirschel-ScholzS, SauratJH, VassalliJD: Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073–1079, 1991

    PubMed  Google Scholar 

  240. HearingVJ, LwaLW, CortiA, AppellaE, BlasiF: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270–1281, 1981

    Google Scholar 

  241. MeissauerA, KramerMD, HofmannM, ErkellLJ, JacobE, SchirrmacherV, BrunnerG: Urokinase type and tissue type plasminogen activators are essential forin vitro invasion of human melanoma cells. Exp Cell Res 192: 453–459, 1991

    PubMed  Google Scholar 

  242. SaitoK, NagashimaM, IwataM, HamadaH, SumiyoshiK, TakadaY, TakadaA: The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res 58: 355–366, 1990

    PubMed  Google Scholar 

  243. AndreasenPA, NielsenLS, KristensenP, Grondahl-HansenJ, SilverL, DanoK: Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator but not its proenzyme. J Biol Chem 261: 7644–7651, 1986

    PubMed  Google Scholar 

  244. RehemtullaA, MurphyP, DobsonM, HartDA: Purification and partial characterization of a plasminogen activator inhibitor from the human glioblastoma U138. Cell Biol 66: 1270–1277, 1988

    Google Scholar 

  245. WilsonEJ, JacobsP, DowdleEB: The effects of dexamethasone and tetradecanoylphorbol acetate on plasminogen activator release by human acute myeloid leukemia cells. Blood 61: 561–567, 1983

    PubMed  Google Scholar 

  246. WilsonEL, JacobsP, DowdleEB: The secretion of plasminogen activators by human myeloid leukemic cellsin vitro. Blood 61: 568–574, 1983

    PubMed  Google Scholar 

  247. WilsonEL, JacobsP, OliverL: Plasminogen activator as a prognostic factor in haematological malignancies. In: NethR (ed) Haematology and Blood Transfusion. Springer-Verlag, Berlin, 1985, pp 197–199

    Google Scholar 

  248. StephensRW, AlitaloR, TapiovaaraH, VaheriA: Production of an active urokinase by leukemia cell lines: A novel distinction from cell lines of solid tumors. Leuk Res 12: 419–422, 1988

    PubMed  Google Scholar 

  249. AlvingBM, KrishnamurtiC, LiuYP, LucasDL, WrightDG: Stimulated production of urokinase by plasminogen activator inhibitor 2 by the human promyelocytic leukemia cell line HL-60. Thromb Res 51: 175–185, 1988

    PubMed  Google Scholar 

  250. OliverLO, KeetonM, WilsonEL: Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562). Blood 74: 1321–1327, 1989

    PubMed  Google Scholar 

  251. TapiovaaraH, VaheriA, AlitaloR, SimPS, WoodrowG, StephensRW: Enhanced activation of prourokinase by human RC2A leukemia cells. Sem Thromb Hemost 17: 251–261, 1991

    Google Scholar 

  252. WilsonEL, JacobsP, FrancisGE, OliverL, BurgerP, DowdleEB: Secretion of plasminogen activators by normal bone marrow cells. Leukaemic myeloid cells. Fibrinolysis 6 (Suppl 1): 77–79, 1992

    Google Scholar 

  253. JanickeF, SchmittM, HafterR, HollreiderA, BabicR, UlmK, GossnerW, GraefJ: Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69–78, 1990

    Google Scholar 

  254. KwaanHC, KeerHN, RadosevichJA, CajotJF, ErnstR: Components of the plasminogen-plasmin system in human tumor cell lines. Sem Thromb Hemost 17: 175–182, 1991

    Google Scholar 

  255. HooseinNM, BoydD, HollasWJ, MazarA, HenkinJ, ChungLWK: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Com 3: 255–264, 1991

    Google Scholar 

  256. WilsonEL, FrancisGE: Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human haemopoietic cells. J Exp Med 165: 1609–1623, 1987

    PubMed  Google Scholar 

  257. Brunner G, Gabrilove J, Rifkin DB, Wilson EL: Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphaatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 114 (in press)

  258. HazudaDJ, StrickerJ, SimonP, YoungPR: Structure-function mapping of interleukin 1 precursors. J Biol Chem 266: 7081–7086, 1991

    PubMed  Google Scholar 

  259. BennettB, BoothA, CrollA, DawsonAA: The bleeding disorder in acute promyelocytic leukemia: Fibrinolysis due to uPA rather than defibrination. Br J Haematol 71: 511–517, 1989

    PubMed  Google Scholar 

  260. SakataY, MurakamiT, NoroA, MoriK, MatsudaM: The specific activity of plasminogen activator inhibitor 1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 77: 1949–1957, 1991

    PubMed  Google Scholar 

  261. KellenJA, MirakianA, KolinA: Antimetastatic effect of amiloride in an animal tumor model. Anticancer Res 8: 1373–1376, 1988

    PubMed  Google Scholar 

  262. OssowskiL, ReichE: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611–619, 1983

    PubMed  Google Scholar 

  263. AxelrodJA, ReichR, MiskinR: Expression of human recombinant metastasis of H-ras-transformed HIH3T3 cells. Mol Cell Biol 9: 2133–2141, 1989

    PubMed  Google Scholar 

  264. PlowEF, FelezJ, MilesLA: Cellular regulation of fibrindysis. Thromb Haemostas 66: 32–36, 1991.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwaan, H.C. The plasminogen-plasmin system in malignancy. Cancer Metast Rev 11, 291–311 (1992). https://doi.org/10.1007/BF01307184

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01307184

Key words

Navigation